Research ArticleMALARIA

Glycolipid-peptide vaccination induces liver-resident memory CD8+ T cells that protect against rodent malaria

See allHide authors and affiliations

Science Immunology  26 Jun 2020:
Vol. 5, Issue 48, eaaz8035
DOI: 10.1126/sciimmunol.aaz8035

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Defending the liver

The liver is an important site of replication for Plasmodium parasites, and therefore a key goal in vaccination against malaria is to induce robust antiparasitic immunity in the liver. Using Plasmodium berghei as a model to study malaria in mice, Holz et al. have developed a glycolipid-peptide conjugate vaccine that induced robust T cell responses in the liver and was able to protect mice when challenged with P. berghei. Inclusion of the glycolipid adjuvant, α-galactosylceramide (α-GalCer) that activates natural killer T (NKT) cells was vital to promoting antiparasitic immunity in the liver. The authors propose that agonists that activate NKT cells could be useful in priming immune responses in the liver in the context of malaria and in other hepatotropic diseases.

View Full Text

Stay Connected to Science Immunology